Activation of the lipid-regulated nuclear receptor, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) modifies the immunophenotype of monocyte-derived dendritic cells (DCs).
INTRODUCTION
Dendritic cells (DCs) are professional antigen presenting cells. They capture, process and present antigen to T cells and thus initiate immune responses or under certain conditions promote immune tolerance. 1 Although several transcription factors have been identified which participate in DC development, the transcriptional regulation of DC differentiation and subtype specification is poorly defined. 2 In particular, the response to a changing milieu and tissue environment is not well understood. More than 30 studies have investigated the genome-wide transcription changes during human DC development and transition to the activated state [3] [4] [5] [6] . Thus, it is well documented that a very large number of genes are regulated during this cytokine driven differentiation program. However beside cytokines, various hormones and lipids also profoundly affect the function and immunophenotype of DCs contributing to lineage, subtype and functional specification. For example DC phenotype is regulated by activation of nuclear hormone receptors such as the glucocorticoid receptor, vitamin D receptor, retinoic acid receptor (RAR) and also PPARs. We and others reported that the lipid regulated nuclear receptor PPARγ is highly and acutely upregulated during DC differentiation [7] [8] [9] . PPARγ is a lipid activated transcription factor that was originally identified by virtue of its role in adipocyte differentiation 10 . This transcription factor directly regulates the expression of several genes participating in fatty acid uptake and lipid storage 11 . The phenotypic effects of PPARγ ligand on DC development has been well characterized, i.e.
PPARγ-instructed DCs have an enhanced phagocytic activity, a modified cytokine production profile, and these cells acquire an elevated NKT cell activating capacity [7] [8] [9] 12 . However it is not clear whether these phenotypic changes are due to direct transcriptional effects on inflammatory gene expression or due to secondary changes induced in lipid metabolism. In order to gain insights into how PPARγ regulates different facets of DC differentiation, we sought to identify PPARγ regulated genes and gene networks in monocyte-derived DCs using unbiased, global gene expression profiling validated by qRT-PCR and complemented by a human genetic model. We employed an exogenous ligand activation approach using a highly selective synthetic ligand (rosiglitazone). In addition, we have defined culture conditions in which human serum induces PPARγ activation via a yet uncharacterized endogenous mechanism. We have found that more than 1000 transcripts (probes sets) were regulated by PPARγ during DC differentiation. We also compared the gene expression profile of DCs obtained from patients 13 harbouring dominant negative mutations of this receptor. Our results indicate that activation of PPARγ acutely upregulated genes primarily involved in lipid metabolism and transport and furthermore, changes in immune function appear to be secondary to these alterations in gene expression.
MATERIALS AND METHODS
Approval was obtained from the institutional review boards of the University of Debrecen and the University of Cambridge for these studies. Informed consent was provided according to the Declaration of Helsinki.
Cell culture and ligand treatment
Monocytes (98% CD14+) were obtained from Buffy coats by Ficoll gradient centrifugation and magnetic separation using anti-CD14-conjugated microbeads (VarioMACS; Miltenyi Biotec). DCs were prepared as described. 9 Cells were cultured in RPMI 1640 (Sigma)
supplemented with 10% FBS (Invitrogen) or with 10% human AB serum (Sigma). To obtain macrophage monocytes were cultured in the presence 100 ng/ml M-CSF (Peprotech) for 5 days. Ligands or vehicle control (50% DMSO/ethanol) were added at Day 0. Cells were treated with rosiglitazone (RSG), GW9662 or GW501516 (Alexis Biochemicals).
Microarray analysis
RNA isolation and labeling was performed as described 14 . Hybridization was carried out at Microarray Core Facility of EMBL (Heidelberg, Germany). Analyses were carried out using GeneSping GX7.3.1 (Agilent) software. Raw data (cell files) were analyzed by GC-RMA algorithm. Data were normalized using per chip normalization (global scaling). First genes (probe sets) were filtered, which had low expression (raw expression < 200 in 90% of the experiments), next probe sets 2 fold up-or downregulated with p-values < 0.01 were selected.
Where indicated hierarchical clustering was performed. To identify overrepresented Gene Ontology (GO) categories Cytoscape/BiNGO (Biological Networks Gene Ontological tool) software was used 15 .
Real-time Quantitative RT-PCR (qRT-PCR)
Real-time Quantitative RT-PCR was conducted as described 14 . The comparative Ct method was used to quantify transcripts and normalize to cyclophilin A expression. In addition, Taqman Low Density Arrays (TLDA) were used ( Figure 4 and 7B), according to manufacturer's instructions. For the TLDA analyses high capacity cDNA archive kit (Applied Biosystems) was used. Quantitative PCR was performed using real-time PCR (ABI PRISM 7900, Applied Biosystems). The sequences of the primers and probes are in Table S5 .
Western-blot analysis
20 μg protein of whole cell extracts was separated by electrophoresis on 12.5% polyacrylamide gel and transferred to PVDF membrane (Bio-Rad Laboratories). Membranes were probed with, anti-FABP4 (Cayman Chemical; rabbit polyclonal ab), the membranes were stripped and re-probed with anti-GAPDH (ab8245-100; Abcam) according to manufacturer's recommendations.
Transient transfections and reporter gene assays
MH100-TK-Luciferase reporter construct were transfected along with the GAL-PPARγ-LBD or GAL-PPARδ-LBD and CMX-β-gal into COS1 cells using jetPEI reagent (Qbiogene). Cells were lysed and assayed for reporter expression 24 hours after transfection. The luciferase and β-galactosidase assay activity was determined as described previously.
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FACS analysis
Cell staining was performed using PE-conjugated monoclonal antibodies and isotype-matched controls (BD PharMingen). The fluorescence of labeled cells was measured by using a FACSCalibur flow cytometer (Beckton Dickinson).
Nile Red Staining
Nile red staining was carried out on unfixed cells as described. 17 In brief, DCs (1-2 x 10 5 /ml) were suspended in PBS then Nile red (Sigma; conc. 5 ng/ml) was added and the cells were incubated for 5 minutes measured by a FACSCalibur flow cytometer (Beckton Dickinson).
Lipid body staining
Osmium tetroxid staining of lipid bodies was performed as described previously 18 .
RESULTS
Exogenous and endogenous activation of the PPARγ pathway during DC development
One of the early genome-wide expression studies indicated that PPARγ is highly upregulated during monocyte-derived DC differentiation 19 . We and others confirmed that the transcript level of PPARγ is immediately and acutely upregulated during DC development, 7-9 and concordant with this effect the bone fide PPARγ target gene (FABP4: adipose specific fattyacid binding protein; also known as aP2) 20 was robustly induced by PPARγ specific ligand treatment 9 . In order to optimize the activation of PPARγ response during DC differentiation we compare the induction of FABP4 using various conditions. When monocytes were cultured in the presence of M-CSF (macrophage differentiation) a weak induction of FABP4 was observed upon PPARγ specific agonist (rosiglitazone; abbreviated as RSG) treatment ( Figure 1A ). In contrast when cells were differentiated towards DCs, in the presence of GM-CSF and IL-4, we obtained a marked upregulation of FABP4 upon PPARγ ligand administration. Remarkably, an elevated expression of FABP4 was detected also in the absence of ligand if the cells were cultured in human serum. ABCG2 a recently described PPARγ target 16 also displayed a similar expression pattern ( Figure 1B ), suggesting that the activity of the receptor can be readily regulated by exogenous as well as endogenous means.
Collectively our data revealed that the optimal condition, providing the largest dynamic range, to study PPARγ response could be achieved if monocytes were cultured in the presence of GM-CSF and IL-4 in FBS containing medium.
Next we sought to optimize the time-course of ligand administration. Our early observations indicated that freshly isolated monocytes lack PPARγ expression, but the mRNA level of PPARγ was immediately and acutely upregulated during DC development. It should be noted, however that the largest PPARγ response was obtained when ligand was added at the beginning of differentiation 9 . Given these considerations we decided to add PPARγ agonist at the beginning of DC differentiation and cells were harvested 6 hours later in order to detect early responses. As 6 hours are obviously not sufficient for DC development, we also harvested the cells 24 hours and after 5 days to compare the genome-wide expression profile of control and PPARγ activated DCs.
Global gene expression profile of exogenous PPARγ ligand treated cells
To monitor whole-genome expression profile during DC development, we selected those transcripts (probes sets) of which expression were changed upon DC differentiation. Global gene expression profiling was performed using Affymetrix GeneChips (HU133 Plus2) and data were obtained from 6 biological replicates. Unexpectedly, a very high number of genes changed during DC development: 14723 probe sets were up-or downregulated if all of the transcripts regulated at any of the time-points were added up ( Figure 2A ). It should be mentioned that numerous genes are covered by more than one probe sets, thus the actual numbers of genes were lower. These results indicated that activation of PPARγ is not a general inhibitor of DC development, because the vast majority of genes, that are regulated upon DC differentiation showed an unaltered expression upon PPARγ ligand treatment ( Figure 2A ). Rather ligand activation appears to modify the differentiation in specific ways.
To select those transcripts that were induced or repressed by PPARγ agonist, we filtered those probe sets, which exhibited changed expression after 6 hours, 24 hours or 5 days of differentiation upon ligand treatment. Therefore we compared the gene expression of untreated versus RSG treated cells at all time-points and selected those probe sets which were at least 2 fold up-or downregulated. As shown on the heatmap in Figure 2B , the expression of 1166 probe sets were altered upon ligand treatment (all of the identified probe sets are presented in Table S1 ). It should be mentioned that a comparable number of probe sets were positively or negatively regulated by PPARγ ligand (633 up; 534 down). Interestingly, after 6 or 24 hours more upregulated genes were detected than down-regulated ones, but by day 5 this trend seemed to be reversed. Furthermore, we detected a large number of transcripts, which were positively regulated across multiple time-points by ligand treatment (40 out of 633). We failed to detect any probe sets, which were downregulated at all time points. Next, we compared the genes regulated by activation of the nuclear receptor to the ones regulated during DC differentiation ( Figure 2C and D). As shown in Figure 2D in DCs harvested at day five, 271 out of 402 genes were induced, in contrast only 38 probe sets were downregulated (DC versus isolated monocytes). These findings suggested that activation of PPARγ negatively regulate a small subset of genes, that are induced during DC development.
Interestingly, approximately 40 percent of the PPARγ ligand upregulated probe sets (146 out of 395 in 5-day-DCs) were also positively regulated upon DC development ( Figure 2C ).
Several well characterized PPARγ targets (ie. FABP4, ADFP) were included in this subgroup.
Interestingly, some of these well known PPAR targets were previously described to be upregulated during DC development 19 indicating that a weak endogenous activation of
PPARγ is likely to occur even if cells are cultured in FBS containing medium. As a conclusion, PPARγ activation does not appear to grossly inhibit the DC differentiation program. Rather it seems to be an integral part of the differentiation and additional activation leads to enhanced expression of a sector of genes.
Activation of PPARγ changes the lipid metabolism/storage of DCs
Next we systematically analyzed the PPARγ regulated genes and investigated the potential role of these genes in DC development and function. To describe the dynamics of DC response upon PPARγ ligand treatment, we classified the regulated genes according to their kinetics of expression and known biological functions. First we analyzed the gene lists containing the PPARγ regulated genes with Cytoscape/BiNGO software 15 to determine which Gene Ontology (GO) categories are over-represented. Remarkably, we observed that only lipid-fatty acid metabolism related categories were over-represented among the genes upregulated by PPARγ ligand after 6 hours ( Figure 3A ; the full dataset is in Table S2 ).
Although several well known PPAR targets were in this list (ABCG1, ANGPTL4, CPT1A CD36) most of the uncovered lipid metabolism related genes were not previously described as a PPARγ regulated gene and most likely several of them are directly and transcriptionally regulated by this receptor ( Figure 3A ). We also analyzed the biological functions of those genes, which were up-regulated after 24 hours and 5 days of ligand treatment. We found that after 24 hours or 5 days besides lipid metabolism, immune response related genes were also highly overrepresented ( Figure 3A ). These data suggest that activation of PPARγ very likely indirectly modifies the immunophenotype of DCs via the activation of metabolic and signaling pathways. It has been shown, that activation of PPARγ receptor modulates the cytokine production, immunogenicity and antigen presenting capacity of DCs. 12 For instance, PPARγ instructed DCs express lower levels of group I CD1s (CD1a, CD1b, CD1c and CD1e)
lipid presenting molecules and CD80 but were characterized by elevated expression of CD1d and CD86. 8, 9 Our gene expression profiling confirmed these previously documented cell surface marker expression changes. For example group I CD1s (CD1a, CD1b and CD1c), as well as CD80 were downregulated following PPARγ ligand administration, in contrast CD1d was positively regulated ( Figure 3A ) indicating that most of the previously described expression changes are regulated at the level of transcription or mRNA stability. In addition, after 24 hours the expression of enzymes involved in collagen degradation (several matrix metallo-proteinases: MMP1, MMP9, MMP10 and MMP12) were downregulated, while adhesion-related molecules were induced by day 5 (Table S2) . Genes associated with Th1 immune response were also down-modulated by day 5 (IRF4, TLR6, INHBA, CD80).
To explore the potential role of the upregulated lipid metabolism associated genes in PPARγ activated DCs we assessed the lipid content of the cells. We did not detect any changes in neutral lipid content using thin layer chromatography (TLC) (data not shown). However Nile 
Validation of microarray expression data with Taqman Low Density Arrays (TLDA)
In order to validate the microarray (GeneChip) results by an independent method we used real-time quantitative RT-PCR (qRT-PCR) utilizing Taqman Low Density Arrays (TLDA).
We selected 174 genes from the gene lists: up or downregulated by PPARγ activators (6 hours or 24 hours). Altogether 136 out of 174 genes (78.2%) were validated by qRT-PCR ( Figure   4 ). We used 3 biological replicates and considered a gene validated if the fold change was at least 1.5 and p < 0.05 (Table S3 ). These results prove that our microarray data are reliable and appropriate for further analyses.
Human serum cultured DCs have enhanced PPARγ activity, evidence for endogenous ligand activation
We observed, as shown in expression of reporter activity was measured upon 10% or 5% human serum exposure ( Figure   5D ). The induction was specific for PPARγ, because using a PPARδ-LBD we failed to detect reporter gene expression upon human serum administration. These data strongly suggest that human serum is likely to contain PPARγ activators or ligand precursors. Figure S1 and Table S4 ). Most importantly, the overlap was almost complete when we compared PPARγ ligand to serum regulated gene sets ( Figure 6A and B).
It should be noted that in these experiments 3 biological replicates were used and that is likely to be the reason for the lower numbers. Together, these findings suggest that human serum [7] [8] [9] . We confirmed these results, in addition, we proved, that these changes were mostly receptor dependent, as administration of a PPARγ antagonist abolished the effect ( Figure 6C ). We found that human serum cultured DCs displayed a similar cell surface expression as PPARγ ligand treated DCs ( Figure 6C ) but some of the markers (CD1d and CD86) showed a higher expression level in human serum cultured cells.
We also added PPARγ specific antagonist (GW9662) to establish receptor-dependency. In the case of CD80 and CD1d we reverted almost completely the effects of human serum, but in the case of CD86 or CD1a we could not revert the phenotype obtained in the presence of FBS suggesting that besides PPARγ activation other pathways are also active.
Impaired PPARγ response in DCs derived from patients harboring a mutated PPARγ gene
One of the main goals of this study was to identify PPARγ receptor-dependent gene expression changes during DC development. One of our concerns was, however that high concentration of PPARγ ligand might elicit a receptor independent response as has been described in PPARγ knock out macrophages. 21 To assess the receptor dependency of gene expression changes, we performed profiling experiments using control or ligand treated DCs 
DISCUSSION
There are multiple reasons to be intrigued by the idea that a lipid activated transcription factor such as PPARγ has a role in human immune cell regulation. One is that this receptor has been intimately linked to lipid metabolism and storage in fat cells and its role in human macrophages and dendritic cells is much less circumscribed and defined. Another is that studying this receptor provides an opportunity to find links between metabolism and immune response, two fields, which are rarely linked at the molecular, transcriptional level. Finally the global effect of activation of PPARγ on the transcriptome in normal primary human cells have not been systematically and exhaustively studied and key questions such as how much activation and repression is mediated by the receptor remains to be answered. In order to address these issues we have designed a robust (six biological replicates), global and unbiased approach to assess the effect of exogenous synthetic ligand (rosiglitazone) activation and endogenous liganding (exposure to human serum) on gene expression changes. The analyses were followed by two validation approaches. One is qRT-PCR and another is using a human genetic model in order to establish receptor dependence. By carrying out this complex study we could determine primary and secondary targets of PPARγ, assess the contribution of the receptor's activation to DC differentiation at the transcriptional level and to compare the effects of a high affinity synthetic ligand to a yet unknown endogenous activator(s).
The global transcription effects of activating PPARγ
A very large amount of data are available about the global gene expression profiles of DCs, especially the immature and activated DCs profiles were extensively compared. [3] [4] [5] [6] It is well established that PPARγ is indispensable for adipocyte formation and this transcription factor is upregulated during adipocyte differentiation. 20 Numerous reports characterized the global gene expression profile of fat cell development using the murine 3T3 L1 preadipocyte model. [22] [23] [24] In contrast to identifying PPARγ regulated genes in myeloid cells only macrophages were analyzed so far 21, [25] [26] [27] and in that system overwhelmingly repressive events have been documented. Most of the available microarray data sets are utilizing mouse cells or mouse tissues and merely a few reports investigated human cells 28, 29 . For this study we obtained expression data from primary human cells derived from normal healthy individuals.
This approach provides us with a unique data set, but also contributes to larger variability. In order to increase the robustness and reliability of the data we used six biological replicates. In addition we employed a very stringent filtering approach as described in the Materials and Methods. We found that using this stringent filtering approach 1166 probe sets were modulated by PPARγ ligand treatment. We could validate around 80% of the selected genes with qRT-PCR irrespective of the usage of any additional statistical tool such as multiple test corrections ( Figure 4 and data not shown). Our results imply that numerous genes are likely to be directly regulated by PPARγ receptor, especially those ones induced after 6 hours of treatment. This is in contrast to previous reports on the gene expression profile of mouse peritoneal macrophages activated by PPARγ activators and it is more likely to reflect differences in the cell types and cell states used rather than species specific differences 27 . This study also establishes that PPARγ acts as a predominantly positive transcription factor rather than a repressor in an immune cell type, because more than half of the regulated genes are positively modulated. It is particularly intriguing that transcriptional repression brought about the receptor's activation is not immediate, but rather occurs over time requiring at least 24 hours to develop ( Figure 2B ).
Genes regulated at early time points are associated with lipid metabolism
We observed that more than 200 probe sets were induced after 6 hours of PPARγ ligand treatment, interestingly in this gene list the category of lipid/fatty acid metabolism was markedly overrepresented, consistent with the presumed role of this receptor in metabolism 11 .
Our understanding of the role of lipid metabolism in DCs remains limited. However our experimental analysis of global lipid changes indicated that PPARγ ligand treated DCs accumulated fewer lipid droplets/bodies suggesting that these cells have an enhanced capacity to metabolize or at least redistribute certain lipids. It is difficult to define which pathways of lipid metabolism are responsible for this regulation, because several identified genes participate in antagonistic processes such as in fatty acid oxidation (ACOX1, HADHSC) or in phospholipid and triacylglicerol synthesis (DGAT2, PPAP2B) and their relative contribution cannot be easily assessed. It should be noted that after 6 hours of cell differentiation a few genes related to lipid/fatty acid uptake and transport (CD36, FABP4) were also induced.
These transporters might contribute to the distribution of intracellular lipids. Interestingly LXRα (NR1H3), the previously described PPARγ target 30 was also upregulated in PPARγ activated DCs. LXRα is a key regulator of lipid and cholesterol metabolism in macrophage 31 .
Interestingly, administration of PPARγ ligand failed to modulate the expression of ABCA1 in human DCs, suggesting that PPARγ dependent LXR response is very limited in this monocyte derived DC model 16 .
PPAR links lipid metabolism and immune function
The data presented here also documents that many more genes were up-or downregulated via PPARγ activation after 24 hours or 5 days than after 6 hours. Interestingly a substantial fraction of these genes were related to immune response. Probably multiple pathways are responsible for this regulation, for example we have recently described that PPARγ activated DCs had an enhanced capacity to produce retinoic acid by inducing retinol and retinal metabolizing enzymes and approximately 30% of the PPARγ ligand regulated genes (at 5 days) was RARα dependent 14 . Similar pathways and mechanisms might exist where changes in metabolism and signaling could contribute direct regulation of immune function associated genes.
The relationship between DC differentiation and PPARγ activation
It is a key issue how activation of PPARγ interferes with DC differentiation at the transcriptional level. Interestingly most of the identified genes, which were negatively regulated upon ligand treatment were induced during DC development suggesting that the receptor's activation inhibits some aspects of DC differentiation (group I CD1s, IL1R1, IL1R2, IRF4, CD80, DCNP1). Several models were proposed for this negative transcriptional, trans-repression/anti-inflammatory effect of PPARγ 32, 33 . Additional 
